JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Search

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

6.65 -0.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

6.42

Max

6.66

Schlüsselkennzahlen

By Trading Economics

Einkommen

30M

-36M

Verkäufe

1.6M

31M

Gewinnspanne

-117.018

Angestellte

181

EBITDA

24M

-40M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+300.6% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-71M

733M

Vorheriger Eröffnungskurs

7.25

Vorheriger Schlusskurs

6.65

Nachrichtenstimmung

By Acuity

50%

50%

162 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Juli 2025, 23:56 UTC

Heiße Aktien

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31. Juli 2025, 23:48 UTC

Market Talk

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31. Juli 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31. Juli 2025, 23:37 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

31. Juli 2025, 23:37 UTC

Market Talk

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31. Juli 2025, 23:12 UTC

Ergebnisse

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31. Juli 2025, 23:10 UTC

Ergebnisse

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31. Juli 2025, 23:09 UTC

Ergebnisse

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31. Juli 2025, 23:08 UTC

Ergebnisse

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31. Juli 2025, 23:08 UTC

Ergebnisse

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31. Juli 2025, 23:01 UTC

Ergebnisse

Amazon Posts Higher Sales, Profit -- 3rd Update

31. Juli 2025, 22:08 UTC

Market Talk
Ergebnisse

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31. Juli 2025, 22:02 UTC

Market Talk
Ergebnisse

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31. Juli 2025, 21:57 UTC

Market Talk
Ergebnisse

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31. Juli 2025, 21:50 UTC

Ergebnisse

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31. Juli 2025, 21:43 UTC

Ergebnisse

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31. Juli 2025, 21:29 UTC

Ergebnisse

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31. Juli 2025, 21:26 UTC

Ergebnisse

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31. Juli 2025, 21:26 UTC

Ergebnisse

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31. Juli 2025, 21:22 UTC

Ergebnisse

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31. Juli 2025, 21:19 UTC

Ergebnisse

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31. Juli 2025, 21:19 UTC

Ergebnisse

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31. Juli 2025, 21:14 UTC

Ergebnisse

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31. Juli 2025, 21:12 UTC

Ergebnisse

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31. Juli 2025, 21:10 UTC

Ergebnisse

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31. Juli 2025, 21:09 UTC

Ergebnisse

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31. Juli 2025, 21:09 UTC

Ergebnisse

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31. Juli 2025, 21:08 UTC

Ergebnisse

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31. Juli 2025, 21:08 UTC

Ergebnisse

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31. Juli 2025, 21:05 UTC

Ergebnisse

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

300.6% Vorteil

12-Monats-Prognose

Durchschnitt 26.88 USD  300.6%

Hoch 36 USD

Tief 18 USD

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

9 ratings

8

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

162 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.